XEN凝胶引流管植入术对青光眼患者降眼压的疗效
回顾性系列病例研究纳入福建医科大学附属第一医院2020年1至9月的8例(8只眼)青光眼患者,行XEN凝胶引流管植入术并随访4至12个月。术前最高眼压中位数28 mmHg,末次随访眼压中位数13 mmHg,青光眼用药中位数由3种降至0种,手术完全成功7例、失败1例,结论认为XEN凝胶引流管植入术是治疗青光眼比较安全且有效的手术方式。
要点
- 8例(8只眼)青光眼患者行XEN凝胶引流管植入术,术后随访4至12个月。
- 术前最高眼压中位数28 mmHg,末次随访眼压中位数13 mmHg,青光眼用药中位数由3种降至0种。
- 截至末次随访手术完全成功7例、失败1例,2例术中前房出血经处理后眼压降至20 mmHg以下。
核心结论
- 小样本初步研究结果显示XEN凝胶引流管植入术是治疗青光眼比较安全且有效的手术方式。
研究设计与样本
- 回顾性系列病例研究,纳入2020年1至9月就诊于福建医科大学附属第一医院的8例(8只眼)青光眼患者,男性6例、女性2例,行XEN凝胶引流管植入术时年龄29至74岁。
- 8例患者包括原发性开角型青光眼7例、青光眼睫状体炎综合征1例;5例既往接受过抗青光眼手术,其余3例未接受手术治疗。
- 所有患者经详细眼科检查后均符合XEN植入术的手术适应证,XEN凝胶引流管植入术均由同一术者完成,所有患者术中均顺利植入XEN凝胶引流管,术后随访4至12个月。
主要发现
- 8例患者术前最高眼压为11至44 mmHg(中位数为28 mmHg,1 mmHg=0.133 kPa),末次随访眼压为10至18 mmHg(中位数为13 mmHg)。
- 术前青光眼用药为2至4种(中位数为3种),末次随访时青光眼用药为0至2种(中位数为0种)。
- 截至末次随访,手术完全成功7例,手术失败1例。
- 2例患者术中出现前房出血,给予积极处理后眼压下降至20 mmHg以下。
- 1例患者因术后3个月引流管阻塞导致眼压再次升高,接受XEN引流管再通手术后眼压下降,末次随访眼压约10 mmHg,未再使用抗青光眼药物治疗,但按标准评估为手术失败;其余患者无其他严重并发症。
关键数值与推荐
- 术前最高眼压11至44 mmHg(中位数为28 mmHg),末次随访眼压10至18 mmHg(中位数为13 mmHg)。
- 术前青光眼用药2至4种(中位数为3种),末次随访青光眼用药0至2种(中位数为0种)。
- 截至末次随访手术完全成功7例、手术失败1例。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论称本研究为小样本初步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Objective: To evaluate the efficacy and safety of the XEN gel implant in the treatment of glaucoma. Methods: It was a retrospective case series study. Eight patients (8 eyes) in the First Affiliated Hospital of Fujian Medical University from January 2020 to September 2020 were included, including six males and two females, aged 29 to 74 years. The patients treated with the XEN gel implanting for glaucoma. After detailed ophthalmic examination, all the patients met the surgical indications for the XEN gel implanting. Preoperative and postoperative intraocular pressure (IOP), anterior segment and fundus examination results, medication, and surgical complications were evaluated. Results: There were seven patients with primary open-angle glaucoma and one patient with glaucomatocyclitic syndrome. Five patients had received anti-glaucoma surgeries, and the remaining three patients had not received surgical treatment. All XEN gel stents were implanted successfully. All patients were followed up for 4 to 12 months. The preoperative maximum IOP ranged from 11 to 44 mmHg (median, 28 mmHg, 1 mmHg=0.133 kPa), and the IOP was 10 to 18 mmHg (median, 13 mmHg) at the last follow-up. Two to 4 types of medication were used for glaucoma preoperatively (median, 3), while 0 to 2 types (median, 0) were used at the last follow-up. During the follow-up, 7 cases were completely successful and only one case failed. Intraoperative hemorrhage occurred in two patients, and after effective treatment, the IOP decreased to below 20 mmHg. One patient was found to have an increased IOP with the XEN luminal obstruction, and the XEN drainage tube was recanalized. The IOP was about 10 mmHg at the last follow-up, and no anti-glaucoma drugs were used, but the surgery was assessed as failure by standard. The remaining patients had no other serious complications. Conclusion: This preliminary study shows that the XEN gel drainage may be a safe and effective treatment for patients with glaucoma. (Chin J Ophthalmol, 2021, 57: 679-684). 目的: 初步评估XEN凝胶引流管植入术在青光眼治疗中的疗效及安全性。 方法: 回顾性系列病例研究。纳入2020年1至9月就诊于福建医科大学附属第一医院的8例(8只眼)青光眼患者的临床资料,其中男性6例,女性2例,行XEN凝胶引流管植入术时患者年龄为29~74岁。所有患者经过详细的眼科检查后,均符合XEN植入术的手术适应证。术后随访的观察指标包括眼压、眼前节、眼底、青光眼用药和手术并发症。 结果: 8例患者包括原发性开角型青光眼7例、青光眼睫状体炎综合征1例。5例患者既往接受过抗青光眼手术。XEN凝胶引流管植入术均由同一术者完成,所有患者术中均顺利植入XEN凝胶引流管,术后随访4~12个月。8例患者术前最高眼压为11~44 mmHg(中位数为28 mmHg)(1 mmHg=0.133 kPa),末次随访眼压为10~18 mmHg(中位数为13 mmHg)。术前青光眼用药为2~4种(中位数为3种),末次随访时青光眼用药为0~2种(中位数为0种)。截至末次随访,手术完全成功7例,手术失败1例。2例患者术中出现前房出血,给予积极处理后眼压下降至20 mmHg以下。1例患者因术后3个月引流管阻塞导致眼压再次升高,接受XEN引流管再通手术后眼压下降,末次随访眼压约10 mmHg,未再使用抗青光眼药物治疗,但按标准评估为手术失败。其余患者无其他严重并发症。 结论: 小样本初步研究结果显示XEN凝胶引流管植入术是治疗青光眼比较安全且有效的手术方式。(中华眼科杂志,2021,57:679-684).
引用
- Yao YH, Ye Q, Wang XH, et al. [Efficacy of the XEN gel stent on intraocular pressure lowering in glaucoma patients]. Zhonghua Yan Ke Za Zhi. 2021. PMID: 34865405. doi:10.3760/cma.j.cn112142-20201223-00841
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。